<DOC>
	<DOCNO>NCT02742090</DOCNO>
	<brief_summary>This Phase 2 , open-label , study TGR-1202 , PI3K delta inhibitor , administer single agent Chronic Lymphocytic Leukemia ( CLL ) patient intolerant prior BTK inhibitor ( ibrutinib , ) prior PI3K delta inhibitor ( idelalisib , )</brief_summary>
	<brief_title>Evaluate Efficacy Safety TGR-1202 Patients With Chronic Lymphocytic Leukemia Who Are Intolerant Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Confirmed diagnosis Chronic Lymphocytic Leukemia ( CLL ) Discontinuation prior BTK inhibitor PI3K delta inhibitor due adverse event within prior 9 month Presence measurable disease Progression prior BTK PI3K delta inhibitor Prior treatment TGR1202 Richter 's transformation CLL transformation aggressive lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CLL</keyword>
</DOC>